Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs

BACKGROUND: Survivin, a member of the inhibitor of apoptosis protein family, is an attractive target for cancer therapy. We have now investigated the effects of the combination of YM155, a novel small-molecule inhibitor of survivin expression, and platinum compounds (cisplatin and carboplatin) on hu...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwasa, T, Okamoto, I, Takezawa, K, Yamanaka, K, Nakahara, T, Kita, A, Koutoku, H, Sasamata, M, Hatashita, E, Yamada, Y, Kuwata, K, Fukuoka, M, Nakagawa, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905296/
https://www.ncbi.nlm.nih.gov/pubmed/20517311
http://dx.doi.org/10.1038/sj.bjc.6605713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905296/
https://www.ncbi.nlm.nih.gov/pubmed/20517311
http://dx.doi.org/10.1038/sj.bjc.6605713

Ejemplares similares